BiotechTube

AVA6000

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Salivary Gland Tumor

Conditions

Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma

Trial Timeline

Jul 16, 2021 → Aug 15, 2026

NCT ID
NCT04969835

About AVA6000

AVA6000 is a phase 1 stage product being developed by Avacta Group for Salivary Gland Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04969835. Target conditions include Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04969835Phase 1Recruiting

Competing Products

11 competing products in Salivary Gland Tumor

See all competitors
ProductCompanyStageHype Score
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
enzalutamideAstellas PharmaPhase 2
52
GefitinibAstraZenecaPhase 2
52
Goserelin Acetate + PembrolizumabMerckPhase 2
52
DovitinibNovartisPhase 2
52
Sacituzumab govitecanGilead SciencesPhase 2
51
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Ipilimumab + NivolumabBristol Myers SquibbPhase 2
51
Darolutamide + GoserelinBayerPhase 2
49
IvonescimabSummit TherapeuticsPhase 2
49
CabozantinibIpsenPhase 2
49

Other Products from Avacta Group

AVA6103Phase 1
25